PPCB · Propanc Biopharma, Inc. · Executive Compensation
$0.85
-0.07 (-7.71%)
At close · Sep 14
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“It is management's opinion that these conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve months from the issue date of this Quarterly Report.”View the 10-Q filed May 14, 2026
Market Cap
$2.10M
Shares
2.28M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Carlo Campiciano | Board of Directors | Appointed | 2026-07-14 |
| Annie Van Broekhoven | Board of Directors | Retired | 2026-07-14 |
| Dr. Ralf Brandt | Board | Appointed | 2026-02-26 |
| Dr. Julian Kenyon | Board of Directors | Retired | 2026-02-26 |
| Annie VanBroekhoven | member of the Company's Board of Directors | Appointed | 2025-08-19 |
| Joseph Himy | member of the Company's Board of Directors | Appointed | 2025-08-19 |
| Jeannine Zimmerman | Chief Financial Officer | Appointed | 2025-08-13 |